Shares of CryoPort Inc (NASDAQ:CYRX) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $19.75.
A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of CryoPort from a “hold” rating to a “buy” rating in a research note on Tuesday, March 19th. ValuEngine raised shares of CryoPort from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st.
In related news, Director Richard J. Berman sold 30,000 shares of CryoPort stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $11.84, for a total value of $355,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 11.00% of the company’s stock.
Shares of CryoPort stock traded up $0.86 on Thursday, reaching $18.24. The company had a trading volume of 1,748 shares, compared to its average volume of 268,306. The company has a market capitalization of $533.15 million, a price-to-earnings ratio of -58.84 and a beta of 1.10. CryoPort has a 52-week low of $8.28 and a 52-week high of $18.11. The company has a debt-to-equity ratio of 0.42, a quick ratio of 11.52 and a current ratio of 11.57.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $6.65 million for the quarter, compared to the consensus estimate of $6.56 million. CryoPort had a negative net margin of 41.61% and a negative return on equity of 28.30%. The business’s revenue was up 65.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.10) EPS. Equities analysts expect that CryoPort will post -0.29 earnings per share for the current year.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Further Reading: What is Put Option Volume?
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.